APPILI THERAPEUTICS INC-CL A(TSX:APLI) stock Fundamental Analysis

Fundamental Rating

APLI gets a fundamental rating of 0 out of 10. The analysis compared the fundamentals against 35 industry peers in the Pharmaceuticals industry. APLI has a bad profitability rating. Also its financial health evaluation is rather negative. APLI is valued expensive and it does not seem to be growing.

Quickly go to:

1. Profitability

1.1 Basic Checks

APLI had negative earnings in the past year.

APLI had a negative operating cash flow in the past year.

APLI had negative earnings in each of the past 5 years.

In the past 5 years APLI always reported negative operating cash flow.

1.2 Ratios

With a Return On Assets value of -188.96%, APLI is not doing good in the industry: 89.19% of the companies in the same industry are doing better.

		Industry Rank	Sector Rank
ROA	-188.96%
ROE	N/A
ROIC	N/A

ROA(3y)-284.09%

ROA(5y)-195.8%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for APLI so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	N/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

APLI does not have a ROIC to compare to the WACC, probably because it is not profitable.

APLI has about the same amout of shares outstanding than it did 1 year ago.

APLI has more shares outstanding than it did 5 years ago.

The debt/assets ratio for APLI is higher compared to a year ago.

2.2 Solvency

APLI has an Altman-Z score of -70.17. This is a bad value and indicates that APLI is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of -70.17, APLI is doing worse than 94.59% of the companies in the same industry.

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Altman-Z	-70.17

ROIC/WACCN/A

WACC11.72%

2.3 Liquidity

A Current Ratio of 0.14 indicates that APLI may have some problems paying its short term obligations.

APLI has a Current ratio of 0.14. This is amonst the worse of the industry: APLI underperforms 89.19% of its industry peers.

A Quick Ratio of 0.14 indicates that APLI may have some problems paying its short term obligations.

APLI has a Quick ratio of 0.14. This is amonst the worse of the industry: APLI underperforms 83.78% of its industry peers.

		Industry Rank	Sector Rank
Current Ratio	0.14
Quick Ratio	0.14

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 21.07% over the past year.

APLI shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -89.13%.

EPS 1Y (TTM)21.07%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-230.77%

Revenue 1Y (TTM)-89.13%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%-77.6%

3.2 Future

Based on estimates for the next years, APLI will show a decrease in Earnings Per Share. The EPS will decrease by 0.00% on average per year.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next Y0%

EPS Next 2Y0%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for APLI. In the last year negative earnings were reported.

Also next year APLI is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

		Industry Rank	Sector Rank
P/FCF	N/A
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2Y0%

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

No dividends for APLI!.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

APPILI THERAPEUTICS INC-CL A

TSX:APLI (3/7/2025, 7:00:00 PM)

0.035

+0.01 (+16.67%)

Chartmill FA Rating

GICS SectorHealth Care

GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences

GICS IndustryPharmaceuticals

Earnings (Last)02-18 2025-02-18

Earnings (Next)06-23 2025-06-23/amc

Inst Owners11.84%

Inst Owner ChangeN/A

Ins Owners0.06%

Ins Owner ChangeN/A

Market Cap4.24M

Analysts42.22

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DPN/A

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)0%

EPS NY rev (3m)0%

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	34.01
P/FCF	N/A
P/OCF	N/A
P/B	N/A
P/tB	N/A
EV/EBITDA	N/A

EPS(TTM)-0.03

EYN/A

EPS(NY)-0.04

Fwd EYN/A

FCF(TTM)-0.01

FCFYN/A

OCF(TTM)-0.01

OCFYN/A

SpS0

BVpS-0.11

TBVpS-0.11

PEG (NY)N/A

PEG (5Y)N/A

Profitability

		Industry Rank	Sector Rank
ROA	-188.96%
ROE	N/A
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	N/A
FCFM	N/A

ROA(3y)-284.09%

ROA(5y)-195.8%

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexcg growth 3YN/A

ROICexcg growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3YN/A

GM growth 5YN/A

F-Score3

Asset Turnover0.06

Health

		Industry Rank	Sector Rank
Debt/Equity	N/A
Debt/FCF	N/A
Debt/EBITDA	N/A
Cap/Depr	17.52%
Cap/Sales	1.92%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	0.14
Quick Ratio	0.14
Altman-Z	-70.17

F-Score3

WACC11.72%

ROIC/WACCN/A

Cap/Depr(3y)72.26%

Cap/Depr(5y)63.36%

Cap/Sales(3y)1.2%

Cap/Sales(5y)N/A

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)21.07%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%-230.77%

EPS Next Y0%

EPS Next 2Y0%

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-89.13%

Revenue growth 3YN/A

Revenue growth 5YN/A

Sales Q2Q%-77.6%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-26.82%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y95.14%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y95.16%

OCF growth 3YN/A

OCF growth 5YN/A

APPILI THERAPEUTICS INC-CL A (APLI.CA) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens